SCHEMBL904938

SCHEMBL904938

CN1C=Nc2ccccc2C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
HPGD P15428 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
TRPA1 O75762 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
ACHE P22303 6/20 0.37
BCHE P06276 3/20 0.37
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
KMT2A Q03164 1/20 0.36
NSD2 O96028 1/20 0.35
CTSD P07339 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013877 0.75 NPC1 (0.55) NPC1HPGDRAB9ASMN1; SMN2TRPA1
SCHEMBL5008184 0.75 NPC1 (0.55) NPC1HPGDRAB9ASMN1; SMN2TRPA1
SCHEMBL2013879 0.75 NPC1 (0.55) NPC1HPGDRAB9ASMN1; SMN2TRPA1
SCHEMBL8340986 0.75 NPSR1 (0.40) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL11799686 0.75 NPC1 (0.50) NPC1HPGDRAB9ASMN1; SMN2TRPA1
SCHEMBL16452796 0.74 NPC1 (0.46) NPC1HPGDRAB9ASMN1; SMN2SIGMAR1
Hydrochloric Acid SCHEMBL5010650 0.73 NPC1 (0.58) NPC1HPGDRAB9ASMN1; SMN2TRPA1
SCHEMBL5139855 0.73 ALDH1A1 (0.50) NPC1HPGDRAB9ASMN1; SMN2SIGMAR1
SCHEMBL29687292 0.73 ALDH1A1 (0.50) NPC1HPGDRAB9ASMN1; SMN2SIGMAR1
SCHEMBL2424631 0.72 NPC1 (0.96) NPC1HPGDRAB9ASMN1; SMN2TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109476641-A Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer 基因泰克公司 2019-03-15 CN disclosed
US-10174011-B2 Heterocyclic compounds, process for preparation of the same and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-01-08 US disclosed
CN-106083899-B Condensed heterocyclic derivates and application method 安姆根有限公司 2018-11-09 CN disclosed
CN-108069959-A A kind of nitrogen-containing hetero cyclics, its preparation method, pharmaceutical composition and application 凯惠科技发展(上海)有限公司 2018-05-25 CN disclosed
US-20170158680-A1 HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-06-08 US disclosed
US-9296782-B2 Inhibitors of hepatitis C virus GILEAD SCIENCES, INC. (US) 2016-03-29 US disclosed
WO-2015020112-A1 DIFLUOROMETHYLENE COMPOUND 石原産業株式会社 (JP) 2015-02-12 WO disclosed
US-8853443-B2 Process for preparing an isocyanate BASF SE (DE) 2014-10-07 US disclosed
US-20140017198-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD PHARMASSET LLC 2014-01-16 US disclosed
CN-103298816-A Substituted pyrazolo-quinazoline derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2013-09-11 CN disclosed
CN-102850336-A DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMA CO LTD 2013-01-02 CN disclosed
WO-2011143444-A2 DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-11-17 WO disclosed
US-20110263892-A1 PROCESS FOR PREPARING AN ISOCYANATE BASF SE (DE) 2011-10-27 US disclosed
CN-101563351-A Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL (IT) 2009-10-21 CN disclosed
US-20080171755-A1 Pyrimidinylpyrazoles as Tgf-Beta Inhibitors LEE WEN-CHERNG 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263892-A1 PROCESS FOR PREPARING AN ISOCYANATE IDH1, IDH2, GMNN NPC1 3131/4885HPGD 15/4885RAB9A 2291/4885
US-10174011-B2 Heterocyclic compounds, process for preparation of the same and use thereof CYP11B2, CYP11B1, ADCYAP1R1 NPC1 64/4885HPGD 93/4885RAB9A 1489/4885
US-20080171755-A1 Pyrimidinylpyrazoles as Tgf-Beta Inhibitors TGFBR1, SMAD3, ALK NPC1 2751/4885HPGD 3075/4885RAB9A 4130/4885
US-20140017198-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, SLC10A1, GOT1 NPC1 20/4885HPGD 623/4885RAB9A 1219/4885
US-20170158680-A1 HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF CYP11B2, CYP11B1, ADCYAP1R1 NPC1 64/4885HPGD 93/4885RAB9A 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.